Hims & Hers Health Inc., a telehealth company based in San Francisco, is facing significant regulatory challenges. On June 23, 2025, Novo Nordisk terminated its collaboration with the company due to allegations that Hims & Hers was promoting and selling illegitimate, knockoff versions of the weight-loss drug Wegovy. These versions, reportedly manufactured by unapproved foreign suppliers in China, posed risks to patient safety by potentially containing dangerous and illicit ingredients. The company also allegedly failed to comply with laws prohibiting mass sales of compounded drugs under the guise of personalization. Following this announcement, Hims & Hers' stock price plummeted by 34.6%, closing at $41.98 per share. Investors affected by these developments are encouraged to participate in pending securities class actions, with a lead plaintiff motion deadline set for August 25, 2025.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.